Leerink analyst Puneet Souda raised his price target for Exact Sciences (EXAS) to $90 from $75 following its co-promotional agreement with Pfizer (PFE). The analyst reiterates an Outperform on Exact Sciences given his view that Cologuard is highly under-penetrated in an 100M-patient strong population where he believes the company could deliver 40%-plus penetration or $6B-plus in revenue longer-term, from just about 3% penetration today.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.